GlucoTrack Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| In thousands of US dollars (except stock data) | ||
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| Current Assets | ||
| Cash and cash equivalents (Note 2D) | 4,492 | 2,312 |
| Other current assets | 376 | 67 |
| Total current assets | 4,868 | 2,379 |
| Property and equipment, net | 27 | 40 |
| Restricted cash (Note 2D) | 10 | 19 |
| TOTAL ASSETS | 4,905 | 2,438 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable | 839 | 672 |
| Other current liabilities | 673 | 341 |
| Total current liabilities | 1,512 | 1,013 |
| Non-current Liabilities | ||
| Loans from stockholders (Note 3) | 196 | 195 |
| Total liabilities | 1,708 | 1,208 |
| Commitments and contingent liabilities (Note 4) | - | - |
| Stockholders’ Equity (Note 5) | ||
| Common Stock of $ 0.001 par value (“Common Stock”): | ||
| 500,000,000 shares authorized as of December 31, 2023 and 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 20 | 15 |
| Additional paid-in capital | 112,966 | 103,095 |
| Receipts on account of shares | 48 | 4 |
| Accumulated other comprehensive income | 16 | 17 |
| Accumulated deficit | (109,853) | (101,901) |
| Total stockholders’ equity | 3,197 | 1,230 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 4,905 | 2,438 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.